进展期胃癌术后紫杉醇联合优福定化疗及同步放疗的临床观察

[目的]评价进展期胃癌根治术后予以紫杉醇联合优福定化疗及同步放疗的疗效及治疗耐受性。[方法]71例进展期胃癌根治术后患者随机分为2个组，同步放化疗组（研究组）37例，采用TAX＋UFT方案放疗，并同步放疗；单纯化疗组（对照组）34例，采用TLF化疗方案。比较两组的治疗毒副反应发生率及1年、3年生存率。[结果]研究组毒副反应发生率（81．1％）高于对照组（67．6％）（P=0．1936）。研究组1年、3年生存率分别为86．5％（32／37）、67．6％（25／37）：对照组分别为64．7％（22／34）、41．2％（14／34）。两组1年、3年生存率比较均有显著性差异（P=0．0317，P=0．0256）。[结论]进展期胃癌根治术后采用紫杉醇联合优福定化疗及同步放疗，与术后单纯化疗相比能显著提高患者的1年、3年生存率；毒副反应能为患者所耐受。

Paclitaxel Combined with Tegafur-Uracil Chemotherapy and Concurrent Radiotherapy for Advanced Gastric Carcinoma Postoperation

[Purpose] To evaluate the clinical efficacy and safety of combined concurrent chemotherapy (paclitaxel tegafur-uracil) and radiotherapy for advanced gastric carcinoma postoper- ation. [Methods] Seventy-one cases with advanced gastric carcinoma after radical gastrectomy were randomly divided into two groups: 37 cases with TAX UFT regimen chemotherapy and radio- therapy(CR group) and 34 cases as control with TLF regimen chemotherapy alone(control group). The toxicity, 1-and 3-year survival rates were compared between the two groups. [Results] The toxicity in CR group was higher than that in control group(81.1% vs. 67.6%)(P=0.1936). One-and 3-year survival were 86.5%, 67.6% in CR group, and 64.7%, 41.2% in CR group, respectively, with significantly difference between the two groups (P=0.0317 for 1-year, P=0.0256 for 3-year). [Conclusions] Postoperative chemotherapy with TAX UFT regimen and concurrent radiotherapy improves the 1-and 3-year survival rates in the patients with advanced gastric carcinoma compared to chemotherapy alone, and the toxicity of chemoradiotherapy is well tolerable.